AbbVie Inc. (NYSE:ABBV) Shares Sold by Pavion Blue Capital LLC

Pavion Blue Capital LLC lessened its stake in AbbVie Inc. (NYSE:ABBVFree Report) by 2.9% during the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 8,426 shares of the company’s stock after selling 250 shares during the period. Pavion Blue Capital LLC’s holdings in AbbVie were worth $1,497,000 as of its most recent SEC filing.

Several other institutional investors have also recently added to or reduced their stakes in the stock. Howard Capital Management Inc. increased its position in AbbVie by 12.2% in the 4th quarter. Howard Capital Management Inc. now owns 21,318 shares of the company’s stock valued at $3,788,000 after acquiring an additional 2,324 shares during the period. Tradewinds Capital Management LLC increased its position in AbbVie by 838.0% in the 4th quarter. Tradewinds Capital Management LLC now owns 4,221 shares of the company’s stock valued at $750,000 after acquiring an additional 3,771 shares during the period. New England Capital Financial Advisors LLC increased its position in AbbVie by 117.1% in the 4th quarter. New England Capital Financial Advisors LLC now owns 788 shares of the company’s stock valued at $140,000 after acquiring an additional 425 shares during the period. Kooman & Associates increased its position in AbbVie by 6.1% in the 4th quarter. Kooman & Associates now owns 3,411 shares of the company’s stock valued at $606,000 after acquiring an additional 195 shares during the period. Finally, TCW Group Inc. increased its position in AbbVie by 5.1% in the 4th quarter. TCW Group Inc. now owns 424,283 shares of the company’s stock valued at $75,395,000 after acquiring an additional 20,645 shares during the period. Institutional investors and hedge funds own 70.23% of the company’s stock.

AbbVie Price Performance

ABBV stock opened at $202.03 on Friday. AbbVie Inc. has a 1 year low of $153.58 and a 1 year high of $207.32. The company has a debt-to-equity ratio of 17.94, a quick ratio of 0.54 and a current ratio of 0.66. The stock’s 50 day moving average price is $181.25 and its 200 day moving average price is $186.42. The firm has a market cap of $356.64 billion, a P/E ratio of 84.18, a PEG ratio of 1.61 and a beta of 0.58.

AbbVie (NYSE:ABBVGet Free Report) last posted its earnings results on Friday, January 31st. The company reported $2.16 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $2.98 by ($0.82). AbbVie had a net margin of 7.59% and a return on equity of 296.28%. During the same period in the previous year, the business posted $2.79 earnings per share. On average, sell-side analysts expect that AbbVie Inc. will post 12.31 earnings per share for the current fiscal year.

AbbVie Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Thursday, May 15th. Shareholders of record on Tuesday, April 15th will be issued a $1.64 dividend. The ex-dividend date is Tuesday, April 15th. This represents a $6.56 annualized dividend and a yield of 3.25%. AbbVie’s dividend payout ratio (DPR) is presently 273.33%.

Analyst Upgrades and Downgrades

ABBV has been the topic of several recent analyst reports. BMO Capital Markets boosted their target price on AbbVie from $208.00 to $215.00 and gave the stock an “outperform” rating in a research report on Monday, February 3rd. Wells Fargo & Company boosted their target price on AbbVie from $195.00 to $210.00 and gave the stock an “overweight” rating in a research report on Monday, February 3rd. UBS Group boosted their target price on AbbVie from $181.00 to $190.00 and gave the stock a “neutral” rating in a research report on Monday, February 3rd. JPMorgan Chase & Co. dropped their target price on AbbVie from $210.00 to $200.00 and set an “overweight” rating on the stock in a research report on Wednesday, November 13th. Finally, Guggenheim boosted their target price on AbbVie from $212.00 to $214.00 and gave the stock a “buy” rating in a research report on Monday, February 3rd. Five investment analysts have rated the stock with a hold rating, seventeen have assigned a buy rating and two have assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $208.35.

View Our Latest Report on AbbVie

Insider Buying and Selling at AbbVie

In other AbbVie news, SVP Kevin K. Buckbee sold 1,800 shares of the business’s stock in a transaction on Monday, December 16th. The stock was sold at an average price of $172.24, for a total value of $310,032.00. Following the completion of the transaction, the senior vice president now directly owns 6,983 shares in the company, valued at approximately $1,202,751.92. The trade was a 20.49 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. 0.25% of the stock is currently owned by insiders.

AbbVie Company Profile

(Free Report)

AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.

Featured Articles

Want to see what other hedge funds are holding ABBV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AbbVie Inc. (NYSE:ABBVFree Report).

Institutional Ownership by Quarter for AbbVie (NYSE:ABBV)

Receive News & Ratings for AbbVie Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AbbVie and related companies with MarketBeat.com's FREE daily email newsletter.